Researchers from Peking Union Medical College Hospital have proposed a framework for agent-based AI systems to support clinical pathology workflows, detailing roles for intelligent agents in slide overview, diagnostic reasoning, and report generation.
VolitionRx reports its finger-prick lateral flow prototype for sepsis shows strong correlation with its automated Nu.Q NETs assay, supporting point-of-care nucleosome testing for critically ill patients.
Proscia’s Concentriq AP-Dx digital pathology platform has received FDA 510(k) clearance for compatibility with the Leica Aperio GT 450 DX scanner and a Predetermined Change Control Plan to streamline future updates.
The company says its US business combines automated kit manufacturing, fulfillment, sample logistics, and digital workflow technology into a single diagnostic testing platform.
The research-use-only platform combines imaging, software, and multiplex protein analysis into a standard 96-well workflow designed to simplify biomarker research.
Research presented at ADLM 2026 indicates immunoassays may significantly underestimate HbA1c in patients with sickle cell trait, suggesting HPLC offers more reliable diabetes screening for populations with hemoglobin variants.
The assay is designed to detect minimal residual disease with greater sensitivity than conventional flow cytometry.
The National Kidney Registry implemented a seven-day serology testing window for organ transplants starting Aug 10, 2026, aligning with new OPTN emergency policies and extending the timeline to all 23 serology tests.
USC researchers report that two blood tests, Lumipulse G p-tau217/β-Amyloid 1-42 and PrecivityAD2, can accurately detect Alzheimer’s pathology in patients with Down syndrome.
SCIEX has launched the ExionLC MD system and updated SCIEX OS software, featuring workflow automation and high-performance UHPLC, to help clinical labs improve productivity, as announced at the ADLM meeting.
ECU Health Medical Center has implemented the bioMérieux VITEK REVEAL analyzer, which identifies effective antibiotics for bloodstream infections about 24 hours faster than standard methods.
The FDA will review GRAIL’s Premarket Approval application for the Galleri multi-cancer early detection blood test on Sept 23, 2026, evaluating data from the PATHFINDER 2 and NHS-Galleri studies.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
The automated urinalysis system integrates chemistry and microscopy to help labs manage higher testing volumes and reduce manual reviews to under 3%, according to the company.